Marc C Chamberlain

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Mechanisms of disease: temozolomide and glioblastoma--look to the future
    Maciej M Mrugala
    Department of Neurology, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98106, USA
    Nat Clin Pract Oncol 5:476-86. 2008
  2. ncbi Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series
    Marc C Chamberlain
    Division of Neuro Oncology, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Ave E, MS G 4940, Seattle, WA, 98109, USA
    J Neurooncol 113:27-32. 2013
  3. ncbi Neoplastic meningitis and metastatic epidural spinal cord compression
    Marc C Chamberlain
    Division of Neuro Oncology, Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Hematol Oncol Clin North Am 26:917-31. 2012
  4. ncbi Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Washington, Seattle, WA 98109, USA
    J Neurooncol 109:143-8. 2012
  5. ncbi Neoplastic meningitis-related prognostic significance of the Karnofsky performance status
    Marc C Chamberlain
    University of Washington, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mail Stop G 4940, Seattle, WA 98109 1023, USA
    Arch Neurol 66:74-8. 2009
  6. ncbi Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 10:547-61. 2010
  7. ncbi Brain metastases: a medical neuro-oncology perspective
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 10:563-73. 2010
  8. ncbi Neurotoxicity of cancer treatment
    Marc C Chamberlain
    Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, MS G4 940, POB 10923, Seattle, WA 98109, USA
    Curr Oncol Rep 12:60-7. 2010
  9. ncbi High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Division of Neuro Oncology Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Neuro Oncol 12:736-44. 2010
  10. ncbi Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington, 98109, USA
    Cancer 116:3988-99. 2010

Detail Information

Publications102 found, 100 shown here

  1. ncbi Mechanisms of disease: temozolomide and glioblastoma--look to the future
    Maciej M Mrugala
    Department of Neurology, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98106, USA
    Nat Clin Pract Oncol 5:476-86. 2008
    ..This Review summarizes new developments in treatment of glioblastoma and speculates on possible future treatment strategies for managing this aggressive cancer...
  2. ncbi Treatment of primary CNS lymphoma (PCNSL) following successful treatment of systemic non-Hodgkin's lymphoma (NHL): a case series
    Marc C Chamberlain
    Division of Neuro Oncology, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Ave E, MS G 4940, Seattle, WA, 98109, USA
    J Neurooncol 113:27-32. 2013
    ..Using a treatment paradigm similar to that utilized for recurrent systemic NHL (induction chemotherapy followed by ASCT) for PCNSL occurring metachronously after successful treatment of systemic NHL appears safe and effective...
  3. ncbi Neoplastic meningitis and metastatic epidural spinal cord compression
    Marc C Chamberlain
    Division of Neuro Oncology, Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Hematol Oncol Clin North Am 26:917-31. 2012
    ....
  4. ncbi Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Washington, Seattle, WA 98109, USA
    J Neurooncol 109:143-8. 2012
    ..5 %) not easily identified pre-treatment, develop serious treatment-related neurological complications that may be persistent and impact quality of life...
  5. ncbi Neoplastic meningitis-related prognostic significance of the Karnofsky performance status
    Marc C Chamberlain
    University of Washington, Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mail Stop G 4940, Seattle, WA 98109 1023, USA
    Arch Neurol 66:74-8. 2009
    ..The prognostic significance of Karnofsky performance status in neoplastic meningitis (NM) has not been demonstrated in patient groups similarly matched for known prognostic variables...
  6. ncbi Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 10:547-61. 2010
    ....
  7. ncbi Brain metastases: a medical neuro-oncology perspective
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 10:563-73. 2010
    ....
  8. ncbi Neurotoxicity of cancer treatment
    Marc C Chamberlain
    Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, MS G4 940, POB 10923, Seattle, WA 98109, USA
    Curr Oncol Rep 12:60-7. 2010
    ..Peripheral nervous system disorders (ie, steroid myopathy, spindle poison, or platinum neuropathy) are predominantly treatment related and respond best to discontinuation of the neurotoxic agent...
  9. ncbi High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Division of Neuro Oncology Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Neuro Oncol 12:736-44. 2010
    ..Overall, PFS ranged from 2 to 80 months (median 21.0). HD-MTX/rituximab and deferred radiotherapy demonstrated similar or better efficacy similar to other HD-MTX-only regimens and reduced time on therapy on average to 6 months...
  10. ncbi Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington, 98109, USA
    Cancer 116:3988-99. 2010
    ....
  11. ncbi Leptomeningeal metastasis
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1023, USA
    Semin Neurol 30:236-44. 2010
    ....
  12. ncbi Anaplastic astrocytomas: biology and treatment
    Marc C Chamberlain
    University of Washington, Department of Neurology and Neurological Surgery, Division of Neuro Oncology, Fred Hutchinson Cancer Research Institute, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 8:575-86. 2008
    ..This treatment paradigm varies considerably from actual practice...
  13. ncbi Neoplastic meningitis: survival as a function of cerebrospinal fluid cytology
    Marc C Chamberlain
    Division of Neuro Oncology, Department of Neurology and Neurological Surgery, University of Washington Fred Hutchinson Cancer Research Institute, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Cancer 115:1941-6. 2009
    ..This retrospective comparison evaluated survival in 2 well-matched cohorts of patients with neoplastic meningitis (NM) presenting with or without positive cerebrospinal fluid (CSF) cytology...
  14. ncbi Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Washington Fred Hutchinson Cancer Center, Seattle, Washington, USA
    Cancer 115:1734-43. 2009
    ..There is no standard therapy for alkylator-resistant AO, and hence a need exists for new therapies...
  15. ncbi Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C
    Marc C Chamberlain
    Department of Neurology, Division of Neuro Oncology, University of Washington, Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109, USA
    J Neurooncol 91:271-7. 2009
    ..The most frequent central nervous system complication of systemic non-Hodgkin's lymphoma (NHL) is lymphomatous meningitis (LM)...
  16. ncbi Neurolymphomatosis: a rare metastatic complication of diffuse large B-Cell lymphoma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Institute, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue East, Mailstop G 4940, PO Box 19023, Seattle, WA 98109 1023, USA
    J Neurooncol 95:285-8. 2009
    ..Neurolymphomatosis, although rare, is increasingly recognized with peripheral and central nervous system MRI. Treatment remains unsatisfactory as treatment with methotrexate-based chemotherapy and irradiation is only partially effective...
  17. ncbi Temozolomide for recurrent intracranial supratentorial platinum-refractory ependymoma
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer 115:4775-82. 2009
    ....
  18. ncbi Salvage therapy with single agent bevacizumab for recurrent glioblastoma
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1023, USA
    J Neurooncol 96:259-69. 2010
    ..5 months). 6-month and 12-month PFS were 42% and 22% respectively. Single agent bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator-refractory GBM...
  19. ncbi Recurrent meningioma: salvage therapy with long-acting somatostatin analogue
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Neurology 69:969-73. 2007
    ..The addition of somatostatin inhibits meningioma growth in vitro in some studies. There have been anecdotal reports of octreotide inhibiting growth in meningiomas...
  20. ncbi Antiangiogenic therapy for high-grade gliomas
    Marc C Chamberlain
    University of Washington, Department of Neurology, Division of Neuro Oncology, Seattle, WA 98109, USA
    CNS Neurol Disord Drug Targets 8:184-94. 2009
    ..Gliomas and in particular high-grade gliomas (HGG) demonstrate when compared to other non-neural solid cancers amongst the highest levels of tumor angiogenesis (the formation of new blood vessels from pre-existing vasculature)...
  21. ncbi Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington, Seattle, WA 98109 1023
    Semin Oncol 36:S35-45. 2009
    ..Until techniques capable of detecting NM early are developed, increased awareness of the disease and standardized evaluation are likely to have the greatest impact on improving diagnosis and implementing earlier treatment...
  22. ncbi Intradural intramedullary spinal cord metastasis due to mesothelioma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109 1023, USA
    J Neurooncol 97:133-6. 2010
    ..Cyberknife radiotherapy. Intramedullary spinal cord metastases, although rare, is increasingly recognized with spinal cord MRI. Treatment remains unsatisfactory as treatment with surgery or irradiation is only partially effective...
  23. ncbi Myelomatous meningitis
    Marc C Chamberlain
    Department of Neurology, University of Washington, Fred Hutchinson Cancer Center, Seattle, Washington 98109, USA
    Cancer 112:1562-7. 2008
    ..Myelomatous meningitis (MM) has been considered rare. The current study was performed to characterize the clinical presentation, treatment, and outcome of MM...
  24. ncbi Leptomeningeal metastasis
    Marc C Chamberlain
    Department of Neurology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Curr Opin Neurol 22:665-74. 2009
    ..Leptomeningeal metastasis occurs in approximately 5% of all patients with cancer. This review summarizes recent literature regarding methods of diagnosis and treatment of leptomeningeal metastasis...
  25. ncbi Risk of neoplastic meningitis following surgical resection of cerebellar metastases
    Marc C Chamberlain
    Department of Neurology and Neurosurgical Surgery, University of Washington, Fred Hutchinson Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109 1023, USA
    J Neurooncol 89:105-7. 2008
    ..Based on limited literature, an at risk group of patients for development of neoplastic meningitis (NM) are those with resected cerebellar parenchymal metastases...
  26. ncbi Extended exposure to alkylator chemotherapy: delayed appearance of myelodysplasia
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, DC, USA
    J Neurooncol 93:229-32. 2009
    ..A case series of gliomas treated with alkylator-based chemotherapy who subsequently developed myelodysplastic syndrome (tMDS) or acute myelocytic leukemia (AML)...
  27. ncbi Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington Fred Hutchinson Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Seattle, WA 98109 102, USA
    J Neurooncol 91:359-67. 2009
    ..Survival ranged from 2 to 23 months (median: 9.0). 6-month and 12-month PFS were 60 and 20%, respectively. Bevacizumab demonstrated efficacy and acceptable toxicity in this cohort of adults with recurrent alkylator refractory AA...
  28. ncbi Radiographic patterns of relapse in glioblastoma
    Marc C Chamberlain
    Division of Neuro Oncology, Department of Neurology and Neurological Surgery, Fred Hutchinson Research Cancer Center, University of Washington, 895 Eastlake Ave, POB Box 19023, MS G4 940, Seattle, WA 98109 1023, USA
    J Neurooncol 101:319-23. 2011
    ..A majority of adult patients with GBM at diagnosis manifest MRI-defined local disease and maintain this pattern notwithstanding multiple recurrences and treatment with bevacizumab...
  29. ncbi Neoplastic meningitis
    Marc C Chamberlain
    Department of Neurology, Division of Neuro Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington 98109 1023, USA
    Oncologist 13:967-77. 2008
    ..Neoplastic meningitis (NM) is a common problem in neuro-oncology, occurring in approximately 5% of all patients with cancer...
  30. ncbi CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Seattle, WA, USA
    J Neurooncol 89:231-8. 2008
    ..A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)...
  31. ncbi Medical treatment of recurrent meningiomas
    Marc C Chamberlain
    Department of Neurology, Division of Neuro Oncology, University of Washington, Fred Hutchinson Research Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4 940, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 11:1425-32. 2011
    ..Clearly, there remains an unmet need in neuro-oncology with respect to the medical treatment of recurrent meningiomas...
  32. ncbi Neuro-oncology: a selected review of ASCO 2011 abstracts
    Marc C Chamberlain
    Department of Neurology, Division of Neuro Oncology, University of Washington, Fred Hutchinson Research Cancer Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mailstop G4 940, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 11:1371-7. 2011
    ..This brief article attempts to highlight select abstracts presented at this years meeting in an organizational manner that will hopefully provide a portrait of the large and multifaceted meeting...
  33. ncbi Adult primary intradural spinal cord tumors: a review
    Marc C Chamberlain
    Department of Neurology Division of Neuro OncologyFred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington, 825 Eastlake Avenue East, POB 19023, MS G4940, Seattle, WA 98109 1023, USA
    Curr Neurol Neurosci Rep 11:320-8. 2011
    ..Treatment consists of surgical resection, and predictors of outcome include preoperative functional status, histologic grade of tumor, and extent of surgical resection...
  34. ncbi Salvage therapy with single agent bendamustine for recurrent glioblastoma
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Washington Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, Mailstop G4 940, Seattle, WA 98109, USA
    J Neurooncol 105:523-30. 2011
    ..Only one patient was progression-free at 6 months, triggering the stopping rule for futility. Bendamustine was reasonably well tolerated but failed to meet the study criteria for activity in adults with recurrent GBM...
  35. ncbi Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas
    Marc C Chamberlain
    Department of Neurology, University of Washington Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1023, USA
    Cancer 113:2146-51. 2008
    ..A phase 2 study was designed to estimate the 6-month progression-free survival of patients with recurrent, treatment-refractory, World Health Organization grade 1 meningiomas who were treated with interferon-alpha...
  36. ncbi Leptomeningeal metastasis
    Marc C Chamberlain
    Department of Neurology, Fred Hutchinson Cancer Research Center, University of Washington, Neuro Oncology Program, Seattle, Wisconsin, USA
    Curr Opin Oncol 22:627-35. 2010
    ..Leptomeningeal metastasis occurs in approximately 3-5% of all patients with cancer. A contemporary literature review of methods of diagnosis and treatment of leptomeningeal metastasis was performed...
  37. ncbi Temozolomide for recurrent low-grade spinal cord gliomas in adults
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington 98109 1023, USA
    Cancer 113:1019-24. 2008
    ..Therefore, a retrospective study of temozolomide (TMZ) in adults with recurrent low-grade spinal cord gliomas with a primary objective of determining progression-free survival (PFS) was performed...
  38. ncbi Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas
    Marc C Chamberlain
    University of Washington, Department of Neurology Division of Neuro Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 10:1537-44. 2010
    ....
  39. ncbi Neoplastic meningitis
    Marc C Chamberlain
    Department of Neurology, Fred Hutchinson Cancer Research Center, University of Washington Neuro Oncology Program, 825 Eastlake Avenue E, Mail stop G 6800, Seattle, WA 98109, USA
    Curr Neurol Neurosci Rep 8:249-58. 2008
    ..Although treatment of NM is palliative, with an expected median patient survival of 3 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM...
  40. ncbi Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Washington, Seattle, Washington 98102, USA
    Neurosurgery 63:720-6; author reply 726-7. 2008
    ..We undertook a retrospectively collected case series of recurrent intracranial HPCs treated with salvage chemotherapy with the primary objective of evaluating progression-free survival...
  41. ncbi Salvage chemotherapy with CPT-11 for recurrent meningioma
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida, 33612, USA
    J Neurooncol 78:271-6. 2006
    ..A prospective Phase II study of irinotecan (CPT-11) in adult patients with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma...
  42. ncbi Temozolomide for treatment-resistant recurrent meningioma
    Marc C Chamberlain
    Department of Neurology, USC Norris Cancer Center, Los Angeles, CA 90033 0804, USA
    Neurology 62:1210-2. 2004
    ..7%). No patient demonstrated a neuroradiographic complete or partial response. Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months); survival ranged from 4 to 9 months (median 7.5 months)...
  43. ncbi Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Center, Tampa, Florida 33612, USA
    Cancer 106:172-9. 2006
    ..A prospective Phase II study of cyclophosphamide (CYC) was conducted in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) with a primary objective of evaluating 6-month progression-free survival (PFS)...
  44. ncbi Combined-modality treatment of leptomeningeal gliomatosis
    Marc C Chamberlain
    Department of Neurology, University of Southern California, Norris Comprehensive Cancer Center and Hospital, Los Angeles, California 90033 0804, USA
    Neurosurgery 52:324-29; discussion 330. 2003
    ..The goal of this study was to determine the toxicity and response rate of combined-modality therapy for the treatment of patients with HGGs and LG...
  45. ncbi Salvage chemotherapy for recurrent spinal cord ependymona
    Marc C Chamberlain
    Department of Neurology, University of Southern California Norris Cancer Center, Los Angeles 90033 0804, USA
    Cancer 95:997-1002. 2002
    ..A prospective Phase II study to determine toxicity and response to chronic oral etoposide in patients with recurrent low-grade intramedullary spinal cord ependymoma (SCE) was conducted...
  46. ncbi Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 0804, USA
    J Neurooncol 82:81-3. 2007
    ..This observation suggests that daily TMZ may represent a potent radiosensitizing regimen...
  47. ncbi Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma
    Marc C Chamberlain
    Department of Neurology, University of Washington, Seattle, WA, USA
    Cancer 112:2038-45. 2008
    ..The primary objective of this prospective phase 2 study of CPT-11 in adult patients with recurrent temozolomide-refractory anaplastic astrocytoma (AA) was to evaluate 6-month progression-free survival (PFS)...
  48. ncbi Role for cytotoxic chemotherapy in patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Fred Hutchinson Cancer Research Center, University of Washington, Seattle Cancer Care Alliance, Seattle, WA, USA
    Expert Rev Neurother 12:929-36. 2012
    ..5 months and 5%, respectively. BEV plus a cytotoxic chemotherapy demonstrated limited efficacy in BEV-refractory GBM and emphasizes an unmet need in neuro-oncology in adults with BEV-refractory GBM...
  49. ncbi Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Division of Neuro Oncology, University of Washington Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    J Neurooncol 104:765-71. 2011
    ....
  50. ncbi Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas
    Marc C Chamberlain
    Department of Neurology, USC Norris Cancer Center, Los Angeles 90033 0804, USA
    J Neurooncol 59:157-63. 2002
    ..A prospective Phase I study designed to establish the maximum tolerated dose and secondarily evaluate response rate to CPT-11 in patients with recurrent oligodendrogliomas (oligos) on anticonvulsant drugs (AEDs)...
  51. ncbi Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme
    Marc C Chamberlain
    Department of Neurology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Cancer 100:1213-20. 2004
    ..The primary objective of the current prospective Phase II study of cyclophosphamide (CYC) in adult patients with recurrent, temozolomide-refractory glioblastoma multiforme was to evaluate 6-month progression-free survival (PFS)...
  52. ncbi Neoplastic meningitis
    Marc C Chamberlain
    Department of Neuro Oncology, University of S Florida, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Suite 3136, Tampa, FL 33612, USA
    J Clin Oncol 23:3605-13. 2005
    ..Although treatment of NM is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM...
  53. ncbi Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme
    Marc C Chamberlain
    University of Southern California, Norris Comprehensive Cancer Hospital, Department of Neurology, Los Angeles 90033 0804, USA
    J Neurooncol 56:183-8. 2002
    ..A prospective Phase II study of CPT-11 in adult patients with recurrent supratentorial glioblastoma multiforme (GBM)...
  54. ncbi A pilot study of primary temozolomide chemotherapy and deferred radiotherapy in elderly patients with glioblastoma
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, 12902 Magnolia Avenue, Tampa, FL 33612 0804, USA
    J Neurooncol 82:207-9. 2007
    ..This pilot study suggests that low dose daily TMZ may represent an alternative and equally effective treatment to more traditionally administered radiotherapy...
  55. ncbi A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
    Jeffrey J Raizer
    Department of Neurology, Northwestern University, Chicago, IL, USA
    Cancer 116:5297-305. 2010
    ..The authors evaluated a 3-week schedule of bevacizumab in patients with recurrent high-grade glioma (HGG)...
  56. ncbi Cerebrospinal fluid-disseminated meningioma
    Marc C Chamberlain
    Department of Neurology, University of Southern California Norris Cancer Center, Lost Angeles, California 90033 0804, USA
    Cancer 103:1427-30. 2005
    ..Meningiomas infrequently metastasize; however, to the authors' knowledge there are limited data regarding the spread of disease through cerebrospinal fluid (CSF)...
  57. ncbi Neoplastic meningitis
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center and Hospital, 1441 Eastlake Avenue, Room 3459, Los Angeles, CA 90033-0804, USA
    Semin Neurol 24:363-74. 2004
    ..Although treatment of neoplastic meningitis is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurological deterioration...
  58. ncbi Neoplastic meningitis
    Alixis Van Horn
    Department of Neurology and Neurological Surgery, University of Washington, Seattle, WA, USA
    J Support Oncol 10:45-53. 2012
    ....
  59. ncbi Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 106:2021-7. 2006
    ..NM reportedly occurs in 1% to 5% of patients with known cancer. Currently available treatment options are limited and provide only modest benefit...
  60. ncbi A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma
    Myrna R Rosenfeld
    Department of Neurology, 3 W Gates, University of Pennsylvania, 3400 Spruce St, Philadelphia, PA 19104, USA
    Neuro Oncol 12:1071-7. 2010
    ..Survival data at 12 and 18 months suggest that this may improve the efficacy of chemoradiation and adjuvant TMZ in this patient population...
  61. ncbi Treatment options for glioblastoma
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 0804, USA
    Neurosurg Focus 20:E19. 2006
    ..The treatments under study include novel cytotoxic chemotherapy as well as small-molecule inhibitors; these are being assessed in a variety of Phase I or II trials...
  62. ncbi Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors
    James Fink
    Department of Radiology, University of Washington, St Louis, MO, USA
    Curr Neurol Neurosci Rep 12:276-85. 2012
    ....
  63. ncbi Pseudoprogression: relevance with respect to treatment of high-grade gliomas
    James Fink
    Department of Radiology, University of Washington, Seattle, USA
    Curr Treat Options Oncol 12:240-52. 2011
    ..e. target) lesion stabilizes or diminishes in size on continued post-radiation (temozolomide) therapy as determined by follow-up radiologic imaging...
  64. ncbi Recurrent spinal cord glioblastoma: salvage therapy with bevacizumab
    Marc C Chamberlain
    Department of Neurology and Neurological Surgery, Seattle Cancer Care Alliance, University of Washington Fred Hutchinson Cancer Research Institute, 825 Eastlake Ave E, POB 19023, MS G4940, Seattle, WA 98109 1023, USA
    J Neurooncol 102:427-32. 2011
    ..Overall median survival was 9 months (range of 5-13 months). Bevacizumab is well tolerated, has tolerable toxicity and apparent activity in this small cohort of adults with recurrent spinal cord glioblastoma...
  65. ncbi Etoposide for recurrent spinal cord ependymoma
    Marc C Chamberlain
    Department of Neurology, USC/Norris Cancer Center, Los Angeles, CA 90033-0804, USA
    Neurology 58:1310-1. 2002
  66. ncbi Neoplastic meningitis-related encephalopathy
    Marc C Chamberlain
    Department of Neurology, University of Southern California, Norris Comprehensive Cancer and Hospital, 1441 Eastlake Avenue, Los Angeles, CA 90033 0804, USA
    J Neurooncol 72:185-9. 2005
    ..A retrospective comparison evaluating survival in two well-matched cohorts of patients with cytologically positive neoplastic meningitis (NM) presenting with or without encephalopathy...
  67. ncbi A phase II trial of intra-cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis
    Marc C Chamberlain
    Department of Neurology, University of Southern California Norris Cancer Center, 1441 Eastlake Ave, Suite 3459, Los Angeles, CA 90033 0804, USA
    Cancer 94:2675-80. 2002
    ..The current study was performed to determine the toxicity and response rate of intra-cerebrospinal fluid (CSF) alpha interferon (alpha-IFN) in the treatment of patients with NM...
  68. ncbi Ependymomas
    Marc C Chamberlain
    Department of Neurology, USC Norris Cancer Center, 1441 Eastlake Avenue, Suite 3459, Los Angeles, CA 90033 0804, USA
    Curr Neurol Neurosci Rep 3:193-9. 2003
    ..Disease-free survival following recurrence is unusual (<15% at 5 years) and suggests intensification of initial adjuvant treatment may best prevent relapse...
  69. ncbi Chemotherapy for brain metastases due to lung cancer and melanoma
    Marc C Chamberlain
    Department of Neurology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1023, USA
    Cancer Treat Res 136:199-213. 2007
  70. ncbi Intracranial meningiomas: an overview of diagnosis and treatment
    Jason Rockhill
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, Washington, USA
    Neurosurg Focus 23:E1. 2007
    ..Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas...
  71. ncbi Intracranial meningiomas: diagnosis and treatment
    Marc C Chamberlain
    Department of Neurology and Neurosurgery, University of Southern California, 1441 Eastlake Ave, Ste 3459, Los Angeles, CA, USA
    Expert Rev Neurother 4:641-8. 2004
    ..g., surgery and radiotherapy) have failed, hormonal chemotherapy may be considered. Notwithstanding limited data, hydroxyurea has been modestly successful in patients with recurrent meningiomas...
  72. ncbi Leukemia and the nervous system
    Marc C Chamberlain
    Department of Neurology, University of Southern California, Norris Comprehensive Cancer Center and Hospital, 1441 Eastlake Avenue, Room 3459, Los Angeles, CA 90033, USA
    Curr Oncol Rep 7:66-73. 2005
    ....
  73. ncbi Leukemic and lymphomatous meningitis: incidence, prognosis and treatment
    Marc C Chamberlain
    Department of Neurology, University of Southern California/Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA
    J Neurooncol 75:71-83. 2005
    ..Using such a risk-stratified approach, the late occurrence of CNS relapse has decreased dramatically attesting to the value of CNS prophylaxis...
  74. ncbi Adult primary spinal cord tumors
    Sean Grimm
    University of Washington, Department of Neurology Division of Neuro Oncology, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, POB 19023, MS G4940, Seattle, WA 98109 1023, USA
    Expert Rev Neurother 9:1487-95. 2009
    ..Primary treatment is surgery in essentially all spinal cord tumors, and predictors of outcome include preoperative functional status, histological grade of tumor and extent of surgical resection...
  75. ncbi Defining patients at risk for neoplastic meningitis: what parameters can be used to determine who should be treated?
    Marc C Chamberlain
    USC Norris Cancer Center, Department of Neurology, 1441 Eastlake Ave, Suite 3459, Los Angeles, CA 90033 0804, USA
    Expert Rev Neurother 4:S3-10. 2004
    ..This discussion initiates the clinical core and practical components of the symposium...
  76. ncbi Treatment of intracranial metastatic esthesioneuroblastoma
    Marc C Chamberlain
    Department of Neurology, University of Southern California, Norris Comprehensive Cancer Center and Hospital, Los Angeles, California 90033 0804, USA
    Cancer 95:243-8. 2002
    ..The current study was conducted to determine the toxicity and response rate of combined modality therapy in the treatment of patients with ENB metastatic to the brain...
  77. ncbi Oligodendroglial tumors
    Sajeel Chowdhary
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33611, USA
    Expert Rev Neurother 6:519-32. 2006
    ..This review provides an overview of oligodendroglial tumors and discusses contemporary and evolving treatment strategies...
  78. ncbi Lymphomatous meningitis in primary central nervous system lymphoma
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, NeuroProgram, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Avenue, Tampa, Florida 33612 0804, USA
    Neurosurg Focus 21:E6. 2006
    ..Patients with primary CNS lymphoma at high risk as defined by positive CSF cytology or neuroradiography consistent with LM may benefit from the inclusion of intra-CSF chemotherapy...
  79. ncbi Neoplastic meningitis
    Marc C Chamberlain
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of Southern Florida, Neuro Oncology Program, Tampa, Florida 33612, USA
    Neurologist 12:179-87. 2006
    ..Neoplastic meningitis (NM) is a common problem in neuro-oncology, occurring in approximately 5% of all patients with cancer...
  80. ncbi Neoplastic meningitis-related encephalopathy: prognostic significance
    Marc C Chamberlain
    Department of Preventive Medicine, USC Norris Cancer Center, University of Southern California, Los Angeles, USA
    Neurology 63:2159-61. 2004
    ..001). NM-related encephalopathy is a clinical variable that predicts for poor survival in patients with NM...
  81. ncbi Gliomatosis cerebri: better definition, better treatment
    Marc C Chamberlain
    Neurology 63:204-5. 2004
  82. ncbi Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis
    Bernard F Cole
    Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Cancer 97:3053-60. 2003
    ..The magnitude of the benefit depends on how the patient values time spent in toxicity and disease progression. The results of this analysis can be used at the bedside to make evidence-based individual treatment decisions...
  83. ncbi Neoplastic meningitis
    Ana Aparicio
    Department of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center and Hospital, 1441 Eastlake Avenue, Room 3459, Los Angeles, CA 90033-0804, USA
    Curr Neurol Neurosci Rep 2:225-35. 2002
    ..Although treatment of NM is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM...
  84. ncbi Treatment of intracranial metastatic esthesioneuroblastoma
    Marc C Chamberlain
    J Clin Oncol 20:357-8. 2002
  85. ncbi Clinical impact of adjuvant chemotherapy in glioblastoma multiforme : a meta-analysis
    Brennan M R Spiegel
    VA Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA
    CNS Drugs 21:775-87. 2007
    ..We sought to update prior analyses by focusing exclusively on GBM, including new trials of novel treatments, assessing effectiveness of individual treatment categories and presenting data in a clinically useful format...
  86. ncbi Adjuvant therapy for unresectable meningiomas: benign and malignant
    Thomas C Chen
    Surgical Neurooncology, University of Southern California, Los Angeles, California, USA
    Neurosurg Focus 23:1. 2007
  87. ncbi Bevacizumab plus irinotecan in recurrent glioblastoma
    Marc C Chamberlain
    J Clin Oncol 26:1012-3; author reply 1013. 2008
  88. ncbi Mafosfamide: a new intra-CSF chemotherapy?
    Marc C Chamberlain
    J Clin Oncol 23:7748-9; author reply 7749. 2005
  89. ncbi A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:208-15. 2008
    ..IVent topotecan is well tolerated, but provides no added benefit over other IVent therapies. Because of its modest side effect profile, combining IVent topotecan with other IVent or systemic interventions should be considered...
  90. ncbi Re: Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
    Marc C Chamberlain
    Blood 110:1698; author reply 1698-9. 2007
  91. ncbi Central nervous system cancers
    Steven S Brem
    H Lee Moffitt Cancer Center and Research Institute
    J Natl Compr Canc Netw 6:456-504. 2008
  92. ncbi Pseudoprogression in glioblastoma
    Marc C Chamberlain
    J Clin Oncol 26:4359; author reply 4359-60. 2008
  93. ncbi Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis
    Stacey L Berg
    Department of Pediatric Oncology, Texas Children's Cancer Center, Baylor College of Medicine, USA
    Curr Oncol Rep 5:29-40. 2003
    ..This article outlines the role of systemic and intrathecal chemotherapy in patients with leptomeningeal metastases. Strategies for symptom management in these patients are also described...
  94. ncbi Intra-CSF rituximab for lymhomatous meningitis
    Marc C Chamberlain
    J Clin Oncol 25:4508-9; author reply 4509-11. 2007
  95. ncbi A neuro-oncologist's perspective on adjuvant radiosurgery for patients with newly diagnosed brain metastases
    Marc C Chamberlain
    Expert Rev Neurother 5:429-31. 2005
  96. ncbi Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas
    Vinay Gupta
    Department of Pathology, University of Southern California, Los Angeles, California 90089, USA
    J Neurosurg 106:455-62. 2007
    ..The authors have investigated the effects of the topoisomerase I inhibitor irinotecan (CPT-11) on primary meningioma cultures and a malignant meningioma cell line in vitro and in vivo...
  97. ncbi MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
    Marc C Chamberlain
    Neurology 67:2089; author reply 2089. 2006
  98. ncbi Regarding "abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial"
    Marc C Chamberlain
    J Clin Oncol 23:1587-8; author reply 1588. 2005
  99. ncbi Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
    Marc C Chamberlain
    Neurology 66:783; author reply 783. 2006
  100. ncbi Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management
    Stacey L Berg
    Norris Cancer Center, University of Southern California, Los Angeles, Ca. 90089, USA
    Cancer Treat Res 125:121-46. 2005
    ..As the majority of patients have widespread incurable systemic tumor, treatment is predominantly palliative; however, some patients with leukemia, lymphoma or breast cancer may have prolonged remissions and the possibility of cure...
  101. ncbi Commentary regarding neoplastic meningitis secondary to multiple myeloma
    Marc C Chamberlain
    Arch Neurol 62:833; author reply 834. 2005